Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD
Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPD
A non-interventional study to assess the clinical effectiveness of Salmeterol/fluticasone
 Easyhaler to achieve and maintain asthma or COPD control.
A prospective, open-label, non-interventional, multicentre study in adult patients with
 asthma or COPD who are treated with Salmeterol/fluticasone Easyhaler. During the study the
 Salmeterol/fluticasone Easyhaler will be used according to the Summary of Product
 Characteristics. Clinical effectiveness of the treatment will be evaluated with change in
 asthma or COPD symptoms during 12 weeks treatment.
Main Inclusion Criteria:

 1. Male or female patients with asthma or COPD who have been using salmeterol/fluticasone
 propionate combination treatment for at least 3 months before the study

 2. Age ≥18 years.

 3. Written informed consent obtained.

 Main Exclusion Criteria:

 1. Pregnant or lactating female patients.

 2. Participation in other clinical studies during the study.

 3. Known hypersensitivity (allergy) to salmeterol, fluticasone propionate or the
 excipient lactose

 4. Any significant medical disease or condition or other factor that might interfere with
 study assessments or study participation.